TransMedics Group, Inc. (TMDX)TMDXTransMedics Group, Inc.

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	635.89M	173.93M	160.76M	143.82M	157.37M	143.54M	121.62M	108.76M	114.31M
Cost of Goods Sold	260.15M	72.77M	67.35M	59.25M	60.78M	55.31M	49.61M	47.92M	45.14M
Gross Profit	375.74M	101.16M	93.41M	84.58M	96.59M	88.23M	72.01M	60.84M	69.16M
Gross Profit Margin	59.1%	58.2%	58.1%	58.8%	61.4%	61.5%	59.2%	55.9%	60.5%
Total Operating Expenses	281.30M	87.86M	72.14M	61.27M	60.02M	60.78M	63.37M	56.92M	56.65M
Research & Development	76.77M	24.88M	20.70M	15.26M	15.93M	17.16M	16.46M	14.27M	13.86M
Selling, General & Administrative	198.47M	56.92M	51.44M	46.02M	44.09M	43.63M	46.91M	42.66M	42.80M
Operating Income (EBIT)	94.44M	13.30M	21.27M	23.30M	36.57M	27.44M	8.64M	3.92M	12.51M
Operating Margin	14.9%	7.6%	13.2%	16.2%	23.2%	19.1%	7.1%	3.6%	10.9%
Income Before Tax (EBT)	89.33M	8.48M	21.63M	23.03M	36.18M	26.68M	6.99M	4.25M	12.15M
Interest Income	5.46M	2.96M	N/A	N/A	2.50M	N/A	2.92M	3.30M	3.40M
Interest Expense	17.49M	7.17M	3.35M	3.49M	3.48M	3.46M	3.57M	3.62M	3.62M
Other Income/Expense	-5.11M	-4.81M	360K	-269K	-385K	-767K	-1.66M	322K	-355K
Net Income	171.92M	7.32M	105.38M	24.32M	34.91M	25.68M	6.86M	4.22M	12.19M
Income Tax Expense	-82.59M	1.17M	-83.75M	-1.29M	1.27M	994K	132K	29K	-41K
Net Profit Margin	27.0%	4.2%	65.6%	16.9%	22.2%	17.9%	5.6%	3.9%	10.7%
EBITDA	127.35M	25.16M	28.74M	30.15M	43.30M	33.58M	14.32M	9.10M	17.11M
EBITDA Margin	20.0%	14.5%	17.9%	21.0%	27.5%	23.4%	11.8%	8.4%	15.0%
Depreciation & Amortization	32.91M	11.86M	7.47M	6.85M	6.73M	6.14M	5.68M	5.18M	4.60M
EPS Basic	5.03	0.21	3.08	0.71	1.03	0.76	0.20	0.13	0.37
EPS Diluted	4.37	0.20	2.59	0.66	0.92	0.70	0.19	0.12	0.35
Shares Outstanding	34.38M	34.38M	34.22M	34.11M	33.91M	33.72M	33.59M	33.44M	33.12M
Diluted Shares Outstanding	36.19M	36.19M	40.93M	40.75M	40.56M	39.91M	35.21M	35.68M	35.29M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	605.49M	441.54M	241.62M	93.46M	30.26M	25.64M	23.60M	13.02M
Cost of Goods Sold	242.69M	179.46M	87.53M	28.19M	9.10M	9.00M	9.74M	7.28M
Gross Profit	362.81M	262.08M	154.09M	65.27M	21.16M	16.64M	13.86M	5.73M
Gross Profit Margin	59.9%	59.4%	63.8%	69.8%	69.9%	64.9%	58.7%	44.1%
Total Operating Expenses	254.22M	224.59M	182.82M	96.71M	60.59M	43.02M	43.47M	25.97M
Research & Development	69.06M	55.97M	63.27M	26.81M	22.30M	18.83M	19.87M	13.66M
Selling, General & Administrative	185.17M	168.62M	119.55M	69.90M	38.28M	24.19M	23.60M	12.31M
Operating Income (EBIT)	108.58M	37.50M	-28.73M	-31.44M	-39.43M	-26.38M	-29.60M	-20.24M
Operating Margin	17.9%	8.5%	-11.9%	-33.6%	-130.3%	-102.9%	-125.4%	-155.5%
Income Before Tax (EBT)	107.52M	35.78M	-26.67M	-36.16M	-44.18M	-28.72M	-33.51M	-23.71M
Interest Income	N/A	N/A	12.50M	900K	N/A	1.65M	790K	N/A
Interest Expense	13.78M	14.41M	10.79M	3.73M	3.87M	3.98M	4.35M	2.42M
Other Income/Expense	-1.06M	-1.72M	2.06M	-4.73M	-4.75M	-2.33M	-3.90M	-3.48M
Net Income	190.29M	35.46M	-25.03M	-36.23M	-44.22M	-28.75M	-33.55M	-23.76M
Income Tax Expense	-82.77M	316K	-1.64M	66K	36K	32K	40K	41K
Net Profit Margin	31.4%	8.0%	-10.4%	-38.8%	-146.1%	-112.1%	-142.1%	-182.5%
EBITDA	135.77M	57.25M	-20.55M	-27.96M	-37.61M	-24.81M	-28.38M	-19.47M
EBITDA Margin	22.4%	13.0%	-8.5%	-29.9%	-124.3%	-96.8%	-120.2%	-149.6%
Depreciation & Amortization	27.18M	19.76M	8.18M	3.48M	1.82M	1.58M	1.22M	769K
EPS Basic	5.60	1.07	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
EPS Diluted	4.87	1.01	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
Shares Outstanding	33.99M	33.23M	32.52M	29.56M	27.62M	24.70M	14.20M	19.25M
Diluted Shares Outstanding	40.54M	35.22M	32.52M	29.56M	27.62M	24.70M	14.20M	19.25M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA

898 employees

www.transmedics.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Waleed H. Hassanein

View full financials